Melissa Fassbender, inPharma, recently published an article about the US Food and Drug Administration (FDA) and the new draft guidance on best practices for drug development. Stephen King, FDA spokesman, stated that the guidance’s purpose “is to describe best practices and procedures for timely, transparent, and effective communications between investigational new drug application (IND) sponsors and FDA at critical junctures in drug development, which may facilitate earlier availability of safe and effect drugs to the American people.” The guidance, being finalized in 18 months, will act as nonbinding recommendations.
Obstacles Facing Biosimilars
Still in its infancy in the U.S., the industry faces some growing pains.
Life Science Accelerated
Our experts are dedicated to expediting life science product development regulatory pathways.